Product Images Perjeta

This is a statistical report for a clinical trial study comparing the effectiveness of different treatments for a medical condition. The hazard ratio (HR) for one treatment compared to the other is 0.62, with a 95% confidence interval of 0.51 to 0.75, which suggests that the treatment with the lower HR is more effective. The p-value obtained is less than 0.0001, indicating statistically significant results. The figure shows the proportion of patients that remain event-free over time, for each treatment group. The treatments being compared are Bertugumab and Trastuzymab + Docotaxel, placebo + Trasilzumad + Bocetaxel, and Pz +T+D with Pa+T+D.*

This appears to be a figure/table containing survival or event-free survival data for two groups of patients receiving different treatments. The first row shows the proportion of patients who remained event-free over time for each treatment group. The p-value and hazard ratio with confidence interval are also provided, suggesting that there may be a statistically significant difference between the two groups. The number of patients at risk is also given for each treatment group over time. However, there is not enough information to determine what type of event was being measured or what the specific treatments were.*

This is a description of Perjeta, a medication that comes in a single-dose vial with a strength of 420 mg/14 mL (30 mg/mL) and the active ingredient Pertuzumab. It should be diluted prior to use and administered via intravenous infusion only. There is no preservative, and unused portions should be discarded. The National Drug Code (NDC) for this medication is 50242-145-01.*